WilmerHale represented Forendo Pharma, a clinical-stage drug development company focused on novel treatments in women’s health, in its acquisition by Organon, a global women’s healthcare company.

Organon acquired Forendo Pharma to bring innovation to the therapeutic area of endometriosis and enable future treatment options in line with the company’s continued focus on creating a robust pipeline that addresses a broad range of conditions impacting women’s health. Forendo’s lead clinical compound in endometriosis is being evaluated for its potential effect on endometriotic lesions, a significant unmet need. The company’s second program is targeting polycystic ovarian syndrome (PCOS) which currently has no approved therapies. The transaction amounts to a total consideration of $954 million.

The WilmerHale team advising Forendo Pharma was led by Hal Leibowitz and Gary Schall and included Alex Bernstein on corporate matters, Ariel Soiffer on licensing and intellectual property matters, Scott Kilgore on employment and benefits matters, Richard Andersen on tax matters, Bruce Manheim on FDA matters, Steve Finizio on international arbitration matters, David Horn on export control matters and David Gold on real estate matters.